Oppenheimer Holdings Stock News

Oppenheimer has upgraded Nektar Therapeutics (NKTR) to outperform from perform given that the stock''s current risk/reward ratio is favorable.

Oppenheimer upgraded Booking Holdings (BKNG) to an Outperform rating after having it slotted with a Perform rating. Read more.

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at Oppenheimer’s 32nd Annual Healthcare Conference on March 16, 2022 at 3:20 pm ET. A live webcast of the presentation will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical

Ghent, Belgium – 09 March 202 2 – Sequana Medical NV ( Euronext Brussels: SEQUA, the “Company” or “Sequana Medical” ) , an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that Ian Crosbie, Chief Executive Officer, will present at the following upcoming investor conferences in March 2022:

GHENT, Belgium, March 09, 2022 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical") , an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that Ian Crosbie, Chief Executive Officer, will present at the following upcoming investor conferences in March 2022: BioCapital Europe , Amsterdam, 10 March 2022 Presentation by Ian Crosbie, CEO, on Thursday 10 March at 15:20 CET Oppenheimer''s 32 nd Annual Healthcare Conference , Virtual format, 15-17 March 2022 Presentation by Ian Crosbie, CEO, on Thursday 17 March at 10:00 am ET / 16:00 CET Sequana Medical will be meeting with international investors in 1-to-1 and small group meetings. Presentation slides will be available on Sequana Medical''s Investors website shortly after the events. For more information, please contact: Sequana Medical Lies Vanneste Director Investor Relations Tel: +32 498 05 35 79 Email: [email protected] LifeSci Advisors Guillaume van Renterghem Tel: +41 76 735 01 31 Email: [email protected] About Sequana Medical Sequana Medical is a commercial stage medical device company utilizing its proprietary alfa pump ® and DSR ® (Direct Sodium Removal) technologies to develop innovative treatments for fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective.

Oppenheimer has started the coverage on the clinical-stage biopharmaceutical company Fulcrum Therapeutics (FULC) with an Outperform recommendation citing the potential of FTX-6058,…

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced that Feng Tian, Ph.D., Chairman of the Board, President, and CEO of Ambrx, will present at Oppenheimer’s 32nd Annual Healthcare Conference taking place March 15-17, 2022. Dr. Tian is scheduled to present on Thursday, March 17, at 12:40 p.m. Eastern Time. Interested parties

CANTON, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in Oppenheimer’s 32nd Annual Healthcare Conference, which is being held virtually from March 15th-16th. Management will present on Tuesday, March 15th at 10:40 a.m. Eastern Time.

Every walk of life has its winners and losers, and this is no different in the land of coronavirus stocks. The term will forever be associated with the pandemic’s p…

ANDOVER, Mass., March 1, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that members of the management team…

FRISCO, Texas--(BUSINESS WIRE)---- $ADUS--Addus HomeCare Corporation (Nasdaq: ADUS), a provider of home care services, today announced that Dirk Allison, Chairman and Chief Executive Officer, Brad Bickham, President and Chief Operating Officer, and Brian Poff, Executive Vice President and Chief Financial Officer, will participate in the Oppenheimer 32nd Annual Healthcare Conference, which is being held as a virtual event. In connection with the conference, there will be a live broadcast and replay of the

SAN DIEGO and TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO , TSX: APS ), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will present and host one-on-one meetings at Oppenheimer''s 32 nd Annual Healthcare Conference: Aptose Presentation - Oppenheimer''s 32nd Annual Healthcare Conference Date: Tuesday, March 15, 2022 Time: 10:00 … Full story available on Benzinga.com

Coinbase Global, Inc. (NASDAQ: COIN ) reported better-than-expected fourth-quarter results but signaled a slower start to fiscal year 2022. The softer outlook sent the shares of the cryptocurrency exchange lower on Friday. The Coinbase Analysts: Oppenheimer analyst Owen Lau maintained an Outperform rating on Coinbase shares and reduced the price target from $444 to $377. Raymond James analyst Patrick O''Shaughnessy maintained an Underperform rating. Rosenblatt Securities analyst Sean Horgan maintained a Buy rating and $262 price target. Needham analyst John Todaro maintained a Buy rating and reduced the price target from $420 to $360. Coinbase Has Multiple Growth Initiatives, Oppenheimer Says: Coinbase reported revenue ahead of expectations, with subscription and service revenue also exceeding estimates, Lau said. Adjusted EBITDA bettered expectations, reflecting lower-than-expected expenses, he added. The increase in cash balance relative to the previous quarter gives the management optionality for internal development, crypto investment and M&A, Lau said.

Two analysts cut their price targets on the stock following the company's latest earnings release.

Oppenheimer (OPY) Board of Directors approved a share repurchase program to purchase up to 518,000 shares.This represents ~4.1% of its 12.53M currently issued and outstanding common stock